RUNX1 has also been shown to exert protection against epithelial-to-mesenchymal transition (EMT) by antagonizing the oncogenic effects of YAP1—a transcription co-factor implicated in breast cancer metastasis [99]. Here, RUNX1 is linked to breast cancer.